
T-DXd Plus THP Bolsters Pathologic Responses in Early-Stage Breast Cancer
Fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) followed by paclitaxel, trastuzumab (Herceptin), and pertuzumab (Perjeta; THP) demonstrated a statistically significant improvement in pathologic complete responses (pCR) vs standard-of-care dose-dense …